Eduardo Alfonso
Known title: DirectorCIK: 0002104484
Eduardo Alfonso's purchase track record
Eduardo Alfonso has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/2/2026 | BLCO | $77K | -16.4% | -5.0% | +11.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| BLCO | ▲ Buy | Grant | 15,842 | $250K | 5/26/2026 | View on chart |
| BLCO | ▲ Buy | Grant | 1,375 | $22K | 4/30/2026 | View on chart |
| BLCO | ▲ Buy | Open Market | 4,300 | $77K | 3/2/2026 | View on chart |
| BLCO | ▲ Buy | Grant | 4,300 | $0 | 3/2/2026 | View on chart |
| BLCO | ▲ Buy | Grant | 5,255 | $0 | 2/19/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
BLCO Advances Oral Dry AMD Treatment After FDA Meeting
Bausch + Lomb reported progress on a new oral drug for dry age‑related macular degeneration after a constructive meeting with the FDA. The company said the discussion helped clarify the regulatory pathway and the drug’s development plan. It also announced that its third‑quarter 2026 earnings will be released on Oct. 28, giving investors a future update on performance.
BLCO Advances Oral Dry AMD Treatment After FDA Meeting. Bausch + Lomb reported progress on a new oral drug for dry age‑related macular degeneration after a constructive meeting with the FDA. The company said the discussion helped clarify the regulatory pathway and the drug’s development plan. It also announced that its third‑quarter 2026 earnings will be released on Oct. 28, giving investors a future update on performance.